Bristol-Myers Squibb Company

Release Summary

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company